What drove BCRX's earnings growth in 2024?

BioCryst Pharmaceuticals' (BCRX) earnings growth in 2024 was primarily driven by the robust performance of its key product, Orldeo, and strategic financial management:

1. **Revenue Growth**: Total revenues reached $450.71 million, with Orldeo contributing significantly. This marked a substantial increase from the previous year, underscoring the product's strong market acceptance and sales momentum.

|code|Ticker|Name|Date|Total Revenue YoY|Total Revenue|market_code|
|---|---|---|---|---|---|---|
|BCRX|BCRX.O|BioCryst Pharmaceuticals|2024 Q1|34.87016197039751|9.2761E7|185|
|BCRX|BCRX.O|BioCryst Pharmaceuticals|2024 Q2|32.53809506491617|1.09332E8|185|
|BCRX|BCRX.O|BioCryst Pharmaceuticals|2024 Q3|34.9807475040926|1.17085E8|185|
|BCRX|BCRX.O|BioCryst Pharmaceuticals|2024 Q4|40.827186004432505|1.31534E8|185|

2. **OrlaDEYO Sales**: Orldeo, particularly in the U.S., experienced robust sales, with $103.1 million in domestic sales and $13.2 million from international markets. Year-over-year growth in Orldeo sales, especially in the U.S., was approximately 34%, highlighting its continued success in the market.
3. **Financial Management**: BioCryst's financial results were bolstered by effective cost management. The company reported an operating profit of $62.9 million, a substantial improvement from the $48.1 million loss in 2023. This shift in profitability trajectory reflects enhanced operational efficiency and strategic financial planning.
4. **Growth Prospects**: The company's growth prospects are further supported by positive developments in product pipeline and market expansion. Successful pediatric Orldeo trials and an anticipated increase in 2025 revenue guidance indicate promising future growth potential.

In summary, BCRX's earnings growth in 2024 was driven by the strong sales of Orldeo, effective financial management, and strategic planning, positioning the company for continued growth and profitability.